Advertisement
Screener

INTENSITY THERAPEUTICS, INC. (INTS) Graph

INTS Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $1.83M; Operating expenses $3.08M; Net income -$3.01M.
  • 2026-03-31: Research and development $1.20M; Operating expenses $2.53M; Net income -$2.43M.
  • 2025-12-31: Research and development $1.50M*; Operating expenses $3.14M*; Net income -$3.05M*.
  • 2025-09-30: Research and development $1.55M; Operating expenses $2.73M; Net income -$2.67M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$1.83M$3.08M-$3.01M
2026-03-31$1.20M$2.53M-$2.43M
2025-12-31$1.50M*$3.14M*-$3.05M*
2025-09-30$1.55M$2.73M-$2.67M
2025-06-30$1.54M$2.71M-$2.54M
2025-03-31$2.19M$3.39M-$3.35M
2024-09-30$2.15M$3.57M-$3.51M
2024-06-30$3.56M$5.07M-$4.97M
2024-03-31$2.81M$4.74M-$4.60M
2023-09-30$1.35M$2.49M-$2.33M
2023-06-30$859.00K$1.22M-$3.70M
2023-03-31$774.00K$1.25M-$1.34M
2022-09-30$1.16M$1.77M-$1.77M
2022-06-30$1.39M$1.93M-$1.93M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$3.03M$5.61M-$5.44M
2025-06-30$3.73M$6.10M-$5.88M
2024-06-30$6.38M$9.81M-$9.57M
2023-06-30$1.63M$2.48M-$5.04M
2022-06-30$3.08M$4.31M-$4.30M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesNet income
2025-09-30$5.28M$8.83M-$8.55M
2024-09-30$8.53M$13.38M-$13.09M
2023-09-30$2.98M$4.97M-$7.37M
2022-09-30$4.24M$6.08M-$6.07M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$6.79M$11.97M$0.00-$11.61M
2024-12-31$10.50M$16.59M$0.00-$16.27M
2023-12-31$4.79M$8.32M$0.00-$10.54M
2022-12-31$5.13M$7.55M$0.00-$7.58M

Similar stocks

Stock NameCountryMarket CapPE Ratio
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
Pluri Inc. (PLUR)$0.014B
IN8BIO, INC. (INAB)United States$0.012B-0.76
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Passage BIO, Inc. (PASG)United States$0.015B-0.43
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
BioCardia, Inc. (BCDA)United States$0.016B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
Jasper Therapeutics, Inc. (JSPR)United States$0.020B-0.37